Pharma BD Deal Intelligence
A deal Abbott tried to walk away from became its single most valuable acquisition ever, thanks to the Alere/Binax rapid-testing platform's COVID-19 windfall — though it also imported hundreds of millions in legacy fraud liabilities and a bungled 2021 supply-chain reversal.
Full analysis, sources & comparables →Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Barclays analyst Jack Meehan said remaining POC players 'carry scarcity value for strategics looking to make inroads,' and Frost & Sullivan's Divyaa…
Crain's framed deal closing as a partial win for Abbott but highlighted that Alere's sales-practice and false-claim issues would continue to drag on…
DOJ joining a 5-year-old false-claim and kickback suit against the Alere business validated Abbott's original 'substantial loss in value' complaint and…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Abbott agreed to acquire Alere for $56/share, ~$5.8B equity value, to become global leader in point-of-care diagnostics. Alere had $2.5B annual sales in infectious disease, molecular, cardiometabolic, and toxicology testing. Combined diagnostics business projected >$7B in sales. Deal later renegotiated to $51/share (~$5.3B); closed October 2017 after litigation.
A deal Abbott tried to walk away from became its single most valuable acquisition ever, thanks to the Alere/Binax rapid-testing platform's COVID-19 windfall — though it also imported hundreds of millions in legacy fraud liabilities and a bungled 2021 supply-chain reversal.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Abbott Laboratories / Alere Inc. (this deal) | 2016 | $5.8B | 95 |
| Abbott Laboratories / Knoll Pharmaceutical Company (BASF Pharma) | 2001 | $6.9B | 100 |
| Abbott Laboratories / Knoll Pharmaceuticals (BASF Pharma) | 2000 | $6.9B | 95 |
| Abbott Laboratories / St. Jude Medical | 2016 | $30.5B | 82 |
| Abbott Laboratories / TheraSense Inc. | 2004 | $1.2B | 81 |
| Abbott Laboratories / Vysis Inc. | 2001 | $355M | 79 |
| Abbott Laboratories / Genentech, Inc. (Roche Group) | 2007 | — | 79 |
← Browse all deals · How we score deals
More: 2016 deals · Abbott Laboratories deals · Infectious Disease deals